Randomised Phase I/II Study with Ghrelin versus Placebo for patients with cancer-related Anorexia/Cachexia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN26185223

Enrollment

Registered

2005-09-12

Start date

2004-03-01

Completion date

Unknown

Last updated

2020-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related anorexia/cachexia Cancer Cancer related disorders

Interventions

Ghrelin intravenous versus placebo.

Eligibility

Inclusion criteria

Inclusion criteria: Patients with any type of advanced, incurable cancer, not requiring new or not being on antineoplastic treatment during the study period, with weight loss (>2% 2 months or >5% 6 months) and anorexia (VAS >3) will be eligible.

Exclusion criteria

Exclusion criteria: Severe structural barriers in the upper gastrointestinal tract, bowel obstruction.

Design outcomes

Primary

Measure	Time frame
1. Safety of parenteral Ghrelin administered in patients with advanced cancer suffering from the anorexia/cachexia syndrome 2. Qualitative and quantitative toxicities	—

Secondary

Measure	Time frame
Symptomatic effect of parenteral Ghrelin on appetite, other anorexia/cachexia related symptoms, and health-related quality-of-life (HRQOL) in patients with advanced cancer suffering from the anorexia/cachexia syndrome. Effect of parenteral Ghrelin on nutritional intake and food preferences.	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026